OverviewSuggest Edit

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. It develops QINPREZO (vosaroxin), an anti-cancer quinolone derivative, or AQD — a class of compounds that has not been used previously for the treatment of cancer. The Company conducts research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology.
TypePublic
Founded1987
HQSouth San Francisco, US
Websitesunesis.com
Employee Ratings4.4

Latest Updates

Employees (est.) (Dec 2018)29(-14%)
Revenue (FY, 2018)$237 K(-64%)
Share Price (Feb 2020)$0.8 (+15%)

Key People/Management at Sunesis Pharmaceuticals

Daniel Swisher

Daniel Swisher

Chief Executive Officer and President

Sunesis Pharmaceuticals Office Locations

Sunesis Pharmaceuticals has an office in South San Francisco
South San Francisco, US (HQ)
395 Oyster Point Blvd
Show all (1)

Sunesis Pharmaceuticals Financials and Metrics

Sunesis Pharmaceuticals Revenue

Sunesis Pharmaceuticals's revenue was reported to be $237 k in FY, 2018
USD

Net income (Q3, 2019)

(5.9m)

EBIT (Q3, 2019)

(6.0m)

Market capitalization (14-Feb-2020)

93.5m

Closing stock price (14-Feb-2020)

0.8

Cash (30-Sept-2019)

19.7m

EV

84.7m
Sunesis Pharmaceuticals's current market capitalization is $93.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

5.0m3.8m8.0m5.7m3.1m2.5m669.0k237.0k

General and administrative expense

8.3m9.2m10.8m23.1m18.7m16.1m13.5m11.3m

R&D expense

22.6m29.2m28.9m27.7m23.7m22.9m21.5m14.6m

Operating expense total

30.9m38.4m39.7m50.8m42.4m39.0m35.1m25.9m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

1.0m1.5m265.0k2.0m2.0m2.0m2.0m2.0m854.0k854.0k854.0k683.0k640.0k610.0k610.0k669.0k237.0k

General and administrative expense

2.0m2.2m2.2m2.2m2.3m2.4m2.9m2.8m3.4m6.4m7.2m5.1m5.2m4.0m4.3m4.0m3.9m3.9m3.7m3.2m3.4m2.8m2.7m2.4m2.5m2.5m

R&D expense

6.0m6.2m6.6m8.1m6.9m7.4m7.7m7.0m7.6m7.2m6.9m4.5m6.3m5.3m6.2m6.6m5.3m6.2m4.9m6.8m4.0m3.8m3.6m3.2m3.7m3.5m

Operating expense total

7.9m8.4m8.8m10.3m9.2m9.8m10.6m9.8m11.0m13.6m14.2m9.6m11.5m9.3m10.5m10.6m9.1m10.1m8.6m9.9m7.3m6.6m6.3m5.7m6.2m6.0m
USDY, 2019

EV/EBIT

-14 x

EV/CFO

-4.6 x

Debt/Equity

0.3 x

Debt/Assets

0.3 x

Financial Leverage

1.3 x
Show all financial metrics

Sunesis Pharmaceuticals Online and Social Media Presence

Embed Graph

Sunesis Pharmaceuticals News and Updates

Sunesis Pharmaceuticals Announces Executive Promotions and Provides Clinical Update

300 mg Cohort of Phase 1b/2 Trial of Vecabrutinib now Enrolling 300 mg Cohort of Phase 1b/2 Trial of Vecabrutinib now Enrolling

Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 15, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic…

Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting

Results to be Further Discussed in Slide Webcast Today at 8:30 p.m. Pacific Time Results to be Further Discussed in Slide Webcast Today at 8:30 p.m. Pacific Time

Sunesis Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 30th Annual Piper Jaffray Healthcare Co…

Sunesis Pharmaceuticals to Host Conference Call on November 5th to Discuss Third Quarter 2018 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 5th, 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended Sep…

Sunesis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 2018 Cantor Global Healthcare Confere…
Show more

Sunesis Pharmaceuticals Frequently Asked Questions

  • When was Sunesis Pharmaceuticals founded?

    Sunesis Pharmaceuticals was founded in 1987.

  • Who are Sunesis Pharmaceuticals key executives?

    Sunesis Pharmaceuticals's key executives are Daniel Swisher.

  • How many employees does Sunesis Pharmaceuticals have?

    Sunesis Pharmaceuticals has 29 employees.

  • What is Sunesis Pharmaceuticals revenue?

    Latest Sunesis Pharmaceuticals annual revenue is $237 k.

  • What is Sunesis Pharmaceuticals revenue per employee?

    Latest Sunesis Pharmaceuticals revenue per employee is $8.2 k.

  • Who are Sunesis Pharmaceuticals competitors?

    Competitors of Sunesis Pharmaceuticals include ORPHELIA Pharma, Phenex Pharmaceuticals and CBT Pharmaceuticals.

  • Where is Sunesis Pharmaceuticals headquarters?

    Sunesis Pharmaceuticals headquarters is located at 395 Oyster Point Blvd, South San Francisco.

  • Where are Sunesis Pharmaceuticals offices?

    Sunesis Pharmaceuticals has an office in South San Francisco.

  • How many offices does Sunesis Pharmaceuticals have?

    Sunesis Pharmaceuticals has 1 office.